Fenfluramine
"Fenfluramine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
Descriptor ID |
D005277
|
MeSH Number(s) |
D02.092.471.683.467
|
Concept/Terms |
Pondimin- Pondimin
- Robins Brand of Fenfluramine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Fenfluramine".
Below are MeSH descriptors whose meaning is more specific than "Fenfluramine".
This graph shows the total number of publications written about "Fenfluramine" by people in this website by year, and whether "Fenfluramine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1986 | 1 | 0 | 1 | 1990 | 1 | 0 | 1 | 1992 | 1 | 0 | 1 | 1993 | 1 | 0 | 1 | 1995 | 0 | 1 | 1 | 1996 | 2 | 0 | 2 | 1997 | 1 | 0 | 1 | 1998 | 2 | 1 | 3 | 1999 | 2 | 0 | 2 | 2003 | 1 | 0 | 1 | 2006 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 | 2014 | 0 | 1 | 1 | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fenfluramine" by people in Profiles.
-
Strzelczyk A, Pringsheim M, Mayer T, Polster T, Klotz KA, Muhle H, Alber M, Trollmann R, Spors H, Kluger G, Kurlemann G, Schubert-Bast S. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany. Epilepsia. 2021 10; 62(10):2518-2527.
-
Kumar AM, Kumar M, Lahey BB, Katz DA, Fernandez B, Shaw JA, Campo A, Nemeroff CB. Marked reduction in serotonergic activity in a sexually aggressive adolescent male. J Neuropsychiatry Clin Neurosci. 2014; 26(3):262-70.
-
Coccaro EF, Lee R, Kavoussi RJ. Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects. Neuropsychopharmacology. 2010 Jan; 35(2):435-44.
-
Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006 Dec; 31(12):2639-51.
-
Lee R, Garcia F, van de Kar LD, Hauger RD, Coccaro EF. Plasma oxytocin in response to pharmaco-challenge to D-fenfluramine and placebo in healthy men. Psychiatry Res. 2003 May 30; 118(2):129-36.
-
Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 1999 Dec 01; 84(11):1335-8.
-
Javed A, Kamradt MC, Van de Kar LD, Gray TS. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 1999 Mar; 90(3):851-8.
-
Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J, Mercier JC, Simonneau G, Dinh-Xuan AT. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998 Oct; 158(4):1061-7.
-
Weir EK, Reeve HL, Johnson G, Michelakis ED, Nelson DP, Archer SL. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest. 1998 Sep; 114(3 Suppl):200S-204S.
-
Javed A, Van de Kar LD, Gray TS. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res. 1998 Apr 27; 791(1-2):67-74.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|